Nearly 70% of Patients Who Take a First-Line Therapy for the Treatment of Schizophrenia Will Progress to a Second-Line Therapy Within 360 Days After Diagnosis
Posted on: Wednesday, 21 December 2005, 09:00 CST
WALTHAM, Mass., Dec. 21 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that of patients who take a first-line therapy for the treatment of schizophrenia, almost 70% will progress to a second-line therapy within a 360-day window after diagnosis. According to the new report entitled Treatment Algorithm Insight Series: Schizophrenia, the high rate of progression in part signals patient and/or physician dissatisfaction with the efficacy or tolerability of a particular drug.
"Although the market tendency is to move patients to a second-line drug within the first year of diagnosis, when you look at it on a drug-by-drug basis you find specific stories that differ from the average," said Alice von Loesecke, senior director at Decision Resources. "For example, only 43% of patients treated with Zyprexa and 46% of patients treated with Risperdal as first-line therapies move on to second-line therapies within the first year of diagnosis."
The new report series from Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) (http://www.pharmetrics.com/) to provide exceptional insight into physicians' actual prescribing trends and drivers of product choice from diagnosis through multiple courses of treatment for a specific disease. The Treatment Algorithm Insight Series examines physicians' actual prescribing behavior as they initiate therapy and move through second- and third-line choices.
Treatment Algorithm Insight Series: Schizophrenia
The report presents a detailed analysis of the treatment of schizophrenia in the United States based on two sources of data -- longitudinal patient- level claims data and primary research. The patient-level data include treatment from initial diagnosis through three lines of therapy and analysis of pathways to key therapies from preceding agents. Insight into the factors driving physician prescribing behavior is drawn from an Internet survey of 78 psychiatrists (all with 20+ schizophrenia cases per month) and 75 PCPs (all with 1+ schizophrenia cases per month).
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- New Treatment Strategy Offers New Hope To RA Patients Who Failed All Other Therapies
- RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
- Surveyed Experts Indicate That Xarelto Has Advantages Over Lovenox in the Treatment of Venous Thromboembolism in Medically Ill Patients
- FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
- New Data Show Preemptive Treatment May Significantly Reduce Skin Toxicities in Patients Receiving Vectibix(R) (Panitumumab)
- Low Levels of Diagnosis and New Biological Approaches to Treatment Indicate a Positive Future for Gastrointestinal Drugs
- Presentation at the 14th International Conference on Prenatal Diagnosis and Therapy Highlights Biocept's I.D.Rh(D) Prenatal Diagnostic
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Aastrom Announces First Patient Treatment With Autologous Stem Cell Therapy for Heart Failure
- New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
 |
 |
User Comments (0)
RSS Feeds